Model-Based Evaluation of the Efficacy and Safety of Burosumab, A Fully Human Anti-FGF23 Monoclonal Antibody, In Adolescent X-Linked Hypophosphatemia (XLH)
Abstract
Authors
J Shi NH Gosselin C Chen R Wang J San Martin
J Shi NH Gosselin C Chen R Wang J San Martin
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now